News & Publications
Fox Chase Cancer Center is a partner with OncLive
(May 21, 2015)
Although recent survey participants expressed an interest in comprehensive tumor genetic profiling, participants with lower income, less education, and non-private insurance were less likely to pursue it if out-of-pocket costs were involved, according to recent study findings.
(May 20, 2015)
Cancer patients are increasingly having their tumors tested using comprehensive genomic profiling (CGP) to identify genetic mutations that can be targeted by precision therapies.
(May 19, 2015)
Researchers from Fox Chase Cancer Center and Temple University recently explored the differences between African-Americans who did and did not participate in a clinical trial and found significant discrepancies in perceptions and beliefs between the two groups.
(May 18, 2015)
Antibody-drug conjugates are a promising option, due to the fact that they can deliver chemotherapy directly into a targeted cell and destroy tumor cells while keeping healthy ones intact.
Fox Chase Annual Report
Temple Health System Publications
Temple Health Magazine